226 related articles for article (PubMed ID: 9667783)
1. Dopaminergic influences on the P300 abnormality in Parkinson's disease.
Sohn YH; Kim GW; Huh K; Kim JS
J Neurol Sci; 1998 Jun; 158(1):83-7. PubMed ID: 9667783
[TBL] [Abstract][Full Text] [Related]
2. [Rasagiline in monotherapy in patients with early stages of Parkinson's disease and in combined and adjunct therapy to levodopa with moderate and advanced stages].
Pagonabarraga J; Rodríguez-Oroz MC
Rev Neurol; 2013 Jan; 56(1):25-34. PubMed ID: 23250679
[TBL] [Abstract][Full Text] [Related]
3. Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group.
Parkinson Study Group
JAMA; 2000 Oct; 284(15):1931-8. PubMed ID: 11035889
[TBL] [Abstract][Full Text] [Related]
4. Dopaminergic induced changes in cognitive and motor processing in Parkinson's disease: an electrophysiological investigation.
Prasher D; Findley L
J Neurol Neurosurg Psychiatry; 1991 Jul; 54(7):603-9. PubMed ID: 1895125
[TBL] [Abstract][Full Text] [Related]
5. P300 in newly diagnosed non-dementing Parkinson's disease: effect of dopaminergic drugs.
Prabhakar S; Syal P; Srivastava T
Neurol India; 2000 Sep; 48(3):239-42. PubMed ID: 11025627
[TBL] [Abstract][Full Text] [Related]
6. Motor response to acute dopaminergic challenge with apomorphine and levodopa in Parkinson's disease: implications for the pathogenesis of the on-off phenomenon.
Colosimo C; Merello M; Hughes AJ; Sieradzan K; Lees AJ
J Neurol Neurosurg Psychiatry; 1996 Jun; 60(6):634-7. PubMed ID: 8648329
[TBL] [Abstract][Full Text] [Related]
7. Drugs for Parkinson's disease.
Treat Guidel Med Lett; 2013 Nov; 11(135):101-6. PubMed ID: 24165688
[TBL] [Abstract][Full Text] [Related]
8. [Are dopamine agonists alternative therapy for levodopa in early stage of Parkinson's disease? No].
Friedman A
Neurol Neurochir Pol; 2007; 41(2 Suppl 1):S10-3. PubMed ID: 17941453
[TBL] [Abstract][Full Text] [Related]
9. The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study.
Bracco F; Battaglia A; Chouza C; Dupont E; Gershanik O; Marti Masso JF; Montastruc JL;
CNS Drugs; 2004; 18(11):733-46. PubMed ID: 15330687
[TBL] [Abstract][Full Text] [Related]
10. Slowing of oscillatory brain activity is a stable characteristic of Parkinson's disease without dementia.
Stoffers D; Bosboom JL; Deijen JB; Wolters EC; Berendse HW; Stam CJ
Brain; 2007 Jul; 130(Pt 7):1847-60. PubMed ID: 17412733
[TBL] [Abstract][Full Text] [Related]
11. [Drug therapy in Parkinson's disease].
van Hilten JJ; Roos RA
Ned Tijdschr Geneeskd; 1999 Jan; 143(5):234-40. PubMed ID: 10086151
[TBL] [Abstract][Full Text] [Related]
12. Lack of independent mood-enhancing effect for dopaminergic medications in early Parkinson's disease.
Espay AJ; Foster ED; Coffey CS; Uribe L; Caspell-Garcia CJ; Weintraub D;
J Neurol Sci; 2019 Jul; 402():81-85. PubMed ID: 31125734
[TBL] [Abstract][Full Text] [Related]
13. Reduction of the postexcitatory cortical inhibition upon paired-click auditory stimulation in patients with Parkinson's disease.
Lukhanina EP; Kapustina MT; Berezetskaya NM; Karaban IN
Clin Neurophysiol; 2009 Oct; 120(10):1852-8. PubMed ID: 19767236
[TBL] [Abstract][Full Text] [Related]
14. Levodopa strengths and weaknesses.
Jankovic J
Neurology; 2002 Feb; 58(4 Suppl 1):S19-32. PubMed ID: 11909982
[TBL] [Abstract][Full Text] [Related]
15. The role of dopamine agonists in early Parkinson's disease.
Watts RL
Neurology; 1997 Jul; 49(1 Suppl 1):S34-48. PubMed ID: 9222273
[TBL] [Abstract][Full Text] [Related]
16. [Medical treatment of Parkinson's disease].
Waldvogel D
Ther Umsch; 2007 Jan; 64(1):15-20. PubMed ID: 17221820
[TBL] [Abstract][Full Text] [Related]
17. Adding a dopamine agonist to preexisting levodopa therapy vs. levodopa therapy alone in advanced Parkinson's disease: a meta analysis.
Talati R; Baker WL; Patel AA; Reinhart K; Coleman CI
Int J Clin Pract; 2009 Apr; 63(4):613-23. PubMed ID: 19222614
[TBL] [Abstract][Full Text] [Related]
18. Effect of rasagiline as adjunct therapy to levodopa on severity of OFF in Parkinson's disease.
Stocchi F; Rabey JM
Eur J Neurol; 2011 Dec; 18(12):1373-8. PubMed ID: 21895884
[TBL] [Abstract][Full Text] [Related]
19. [The effectiveness and tolerance of piribedil as adjunct therapy to levodopa in patients with Parkinson's disease: a nine month follow up].
Salazar Tortolero G; Wix Ramos R; Salazar Aladrén P; Jiménez León JC
Rev Neurol; 2004 Apr 16-30; 38(8):715-9. PubMed ID: 15122540
[TBL] [Abstract][Full Text] [Related]
20. Parkinson's disease: medical treatment of moderate to advanced disease.
Suchowersky O
Curr Neurol Neurosci Rep; 2002 Jul; 2(4):310-6. PubMed ID: 12044250
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
